Natural Product (NP) Details
| General Information of the NP (ID: NP2974) | |||||
|---|---|---|---|---|---|
| Name |
Mangiferin
|
||||
| Synonyms |
Mangiferin; 4773-96-0; Alpizarin; Chinonin; Chinomin; Hedysarid; Aphloiol; Alpizarine; Shamimin; UNII-1M84LD0UMD; 1M84LD0UMD; CHEBI:6682; 2-beta-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one; 9H-Xanthen-9-one, 2-b-D-glucopyranosyl-1,3,6,7-tetrahydroxy-; (1S)-1,5-anhydro-1-(1,3,6,7-tetrahydroxy-9-oxo-9H-xanthen-2-yl)-D-glucitol; MFCD00075656; 9H-Xanthen-9-one, 2-beta-D-glucopyranosyl-1,3,6,7-tetrahydroxy- (9CI); 1,3,6,7-Tetrahydroxyxanthone-C2-b-D-glucoside; Chedisaride; Euxanthogen; Hedysaride; Mannipherin; Chinoinin; Chinomine; 1,3,6,7-Tetrahydroxy-2-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-9H-xanthen-9-one; 9H-Xanthen-9-one, 2-.beta.-D-glucopyranosyl-1,3,6,7-tetrahydroxy-; cid_5358385; Alpizarine;; Mangiferin;; Aphloiol;; Chinomin;; NSC248870; Mangiferin,(S); Xanthone-c-glucoside; NSC 248870; 1,3,6,7-tetrahydroxyxanthone C2-beta-D-glucoside; 9H-Xanthen-9-one, 2-beta-D-glucopyranosyl-1,3,6,7-tetrahydroxy-; Mangiferin Mangifera indica; SCHEMBL556844; Mangiferin, analytical standard; CHEMBL464825; BCBcMAP01_000240; DTXSID60197263; HY-N0290; ZINC4098535; BDBM50248691; s3808; STL564509; AKOS015896788; CCG-268909; CS-4663; MCULE-3926908782; SMP1_000290; AS-15337; O907; N1329; A12088; C10077; 773M960; Q-100508; Q1074417; c2-beta-d-glucopyranosyl-1,3,6,7-tetrahydroxyxanthone; Mangiferin, European Pharmacopoeia (EP) Reference Standard; 1,3,6,7-tetrahydroxy-2-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]xanthen-9-one
Click to Show/Hide
|
||||
| Species Origin | Mangifera indica ... | Click to Show/Hide | |||
| Mangifera indica | |||||
| Disease | Cardiac fibrosis [ICD-11: DB98] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-6.235
MDCK Permeability
-5.032
PAMPA
+++
HIA
++
Distribution
VDss
-0.087
PPB
81.8%
BBB
- - -
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
- - -
CYP2C19 inhibitor
- - -
CYP2C19 substrate
- - -
CYP2C9 inhibitor
- - -
CYP2C9 substrate
- - -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- - -
CYP3A4 inhibitor
- - -
CYP3A4 substrate
- - -
CYP2B6 inhibitor
- - -
CYP2B6 substrate
- - -
CYP2C8 inhibitor
+++
HLM Stability
- - -
Excretion
CLplasma
3.951
T1/2
4.548
Toxicity
DILI
+++
Rat Oral Acute Toxicity
- -
FDAMDD
- -
Respiratory
- - -
Human Hepatotoxicity
-
Ototoxicity
++
Drug-induced Nephrotoxicity
- - -
Drug-induced Neurotoxicity
- - -
Hematotoxicity
- - -
Genotoxicity
+++
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C19H18O11
|
||||
| PubChem CID | |||||
| Canonical SMILES |
C1=C2C(=CC(=C1O)O)OC3=C(C2=O)C(=C(C(=C3)O)C4C(C(C(C(O4)CO)O)O)O)O
|
||||
| InChI |
1S/C19H18O11/c20-4-11-15(25)17(27)18(28)19(30-11)12-8(23)3-10-13(16(12)26)14(24)5-1-6(21)7(22)2-9(5)29-10/h1-3,11,15,17-23,25-28H,4H2/t11-,15-,17+,18-,19+/m1/s1
|
||||
| InChIKey |
AEDDIBAIWPIIBD-ZJKJAXBQSA-N
|
||||
| CAS Number |
CAS 4773-96-0
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Oxaliplatin | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HT29 | CVCL_A8EZ | Colorectal adenocarcinoma | Mus musculus | ||
| Experimental
Result(s) |
Mangiferin in combination with oxaliplatin favours apoptotic cell death and thereby improves the efficacy of oxaliplatin in vitro. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Aldose reductase (AKR1B1) | Molecule Info | [3] | |
| Influenza Neuraminidase (Influ NA) | Molecule Info | [4] | ||
| BioCyc | Methylglyoxal degradation III | Click to Show/Hide | ||
| 2 | Acetone degradation I (to methylglyoxal) | |||
| KEGG Pathway | Other glycan degradation | Click to Show/Hide | ||
| 2 | Pentose and glucuronate interconversions | |||
| 3 | Fructose and mannose metabolism | |||
| 4 | Galactose metabolism | |||
| 5 | Glycerolipid metabolism | |||
| 6 | Metabolic pathways | |||
| NetPath Pathway | IL1 Signaling Pathway | Click to Show/Hide | ||
| 2 | TGF_beta_Receptor Signaling Pathway | |||
| Pathwhiz Pathway | Fructose and Mannose Degradation | Click to Show/Hide | ||
| 2 | Pyruvate Metabolism | |||
| 3 | Pterine Biosynthesis | |||
| 4 | Glycerolipid Metabolism | |||
| 5 | Galactose Metabolism | |||
| WikiPathways | Metapathway biotransformation | Click to Show/Hide | ||
| 2 | Polyol Pathway | |||
| 3 | Metabolism of steroid hormones and vitamin D | |||